Kezar Life Sciences (KZR) Competitors $6.38 -0.14 (-2.15%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends KZR vs. ALEC, LYEL, CHRS, OGI, AMRN, GNFT, OPT, SLDB, KYTX, and GOSSShould you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Alector (ALEC), Lyell Immunopharma (LYEL), Coherus BioSciences (CHRS), Organigram (OGI), Amarin (AMRN), Genfit (GNFT), Opthea (OPT), Solid Biosciences (SLDB), Kyverna Therapeutics (KYTX), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. Kezar Life Sciences vs. Alector Lyell Immunopharma Coherus BioSciences Organigram Amarin Genfit Opthea Solid Biosciences Kyverna Therapeutics Gossamer Bio Alector (NASDAQ:ALEC) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends. Which has more risk and volatility, ALEC or KZR? Alector has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Which has stronger valuation and earnings, ALEC or KZR? Kezar Life Sciences has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlector$61.51M2.96-$130.39M-$1.70-1.09Kezar Life Sciences$7M6.65-$101.87M-$13.18-0.48 Does the MarketBeat Community favor ALEC or KZR? Alector received 19 more outperform votes than Kezar Life Sciences when rated by MarketBeat users. Likewise, 61.02% of users gave Alector an outperform vote while only 56.90% of users gave Kezar Life Sciences an outperform vote. CompanyUnderperformOutperformAlectorOutperform Votes15561.02% Underperform Votes9938.98% Kezar Life SciencesOutperform Votes13656.90% Underperform Votes10343.10% Do insiders and institutionals hold more shares of ALEC or KZR? 85.8% of Alector shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 9.1% of Alector shares are owned by insiders. Comparatively, 9.3% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate ALEC or KZR? Alector currently has a consensus price target of $3.75, suggesting a potential upside of 101.61%. Kezar Life Sciences has a consensus price target of $39.50, suggesting a potential upside of 519.12%. Given Kezar Life Sciences' higher probable upside, analysts plainly believe Kezar Life Sciences is more favorable than Alector.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.14Kezar Life Sciences 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ALEC or KZR more profitable? Kezar Life Sciences has a net margin of 0.00% compared to Alector's net margin of -257.54%. Kezar Life Sciences' return on equity of -54.95% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Alector-257.54% -108.77% -27.03% Kezar Life Sciences N/A -54.95%-46.11% Does the media prefer ALEC or KZR? In the previous week, Alector had 9 more articles in the media than Kezar Life Sciences. MarketBeat recorded 11 mentions for Alector and 2 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of -0.37 beat Alector's score of -0.37 indicating that Kezar Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Kezar Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAlector beats Kezar Life Sciences on 10 of the 18 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZR vs. The Competition Export to ExcelMetricKezar Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.57M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-0.4810.5991.3417.19Price / Sales6.65195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book0.255.104.794.78Net Income-$101.87M$151.51M$120.07M$225.60M7 Day Performance-5.48%-2.14%-1.90%-1.24%1 Month Performance-16.27%-3.13%11.43%3.06%1 Year Performance-24.26%11.51%30.59%16.50% Kezar Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZRKezar Life Sciences3.7081 of 5 stars$6.38-2.1%$39.50+519.1%-25.0%$47.57M$7M-0.4860Analyst ForecastNews CoverageALECAlector4.2493 of 5 stars$1.99+1.0%$4.00+101.0%-76.4%$194.89M$61.51M-1.16270Analyst DowngradeLYELLyell Immunopharma2.2251 of 5 stars$0.66-1.6%$1.00+50.8%-69.1%$193.76M$63,000.00-0.85270Gap DownCHRSCoherus BioSciences4.0914 of 5 stars$1.68+4.3%$5.38+219.9%-21.6%$193.56M$304.34M-20.13246OGIOrganigram0.7654 of 5 stars$1.53+3.4%N/A+27.9%$193.04M$120.01M-3.65860Earnings ReportAnalyst RevisionNews CoverageAMRNAmarin0.0303 of 5 stars$0.47+3.0%N/A-42.6%$192.61M$241.02M-5.06360Analyst ForecastGNFTGenfit1.1979 of 5 stars$3.85+0.8%$13.00+237.7%+2.2%$192.46M$41.31M0.00120Positive NewsOPTOpthea2.5742 of 5 stars$3.26+0.3%$12.00+268.1%+31.5%$190.37M$124,666.000.008Analyst UpgradeNews CoverageSLDBSolid Biosciences4.0837 of 5 stars$4.75-3.3%$15.22+220.5%-15.8%$189.81M$8.09M-1.61100KYTXKyverna Therapeutics2.4246 of 5 stars$4.36-1.4%$25.71+489.8%N/A$188.23M$7.03M0.0096News CoverageGOSSGossamer Bio3.622 of 5 stars$0.83-10.7%$9.20+1,007.8%-1.4%$188.20M$105.32M-2.61180 Related Companies and Tools Related Companies ALEC Competitors LYEL Competitors CHRS Competitors OGI Competitors AMRN Competitors GNFT Competitors OPT Competitors SLDB Competitors KYTX Competitors GOSS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KZR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KZR Stock Alerts